<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541006</url>
  </required_header>
  <id_info>
    <org_study_id>Neu-21.12</org_study_id>
    <nct_id>NCT02541006</nct_id>
  </id_info>
  <brief_title>Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD</brief_title>
  <official_title>A Randomized, Parallel-group, Phase IV Study to Compare the Bronchodilator Efficacy of Tiotropium (18 µg Once Daily [od]) Delivered Via a DISCAIR With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the bronchodilator efficacy a of tiotropium
      inhalation via DISCAIR (18 mcg once daily) and SPIRIVA HANDIHALER® (18 mcg once daily) in
      patients with moderate to severe chronic obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median maximum change (ml) from baseline in Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC)</measure>
    <time_frame>prior to the first dose of randomised study medication. Then, 15 minutes (min), 30 min,1 hour (h),2h,3h,4h,6h,8h,12 h and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percantage (%) change from baseline in FEV1 and FVC</measure>
    <time_frame>prior to the first dose of randomised study medication. Then, 15 minutes (min), 30 min,1 hour (h),2h,3h,4h,6h,8h,12 h and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized Area Under the Curve (AUC) Between Baseline (Pre-dose) and 24 Hours -Post-dose</measure>
    <time_frame>Baseline FEV1 taken at visit 2 prior to the first dose of randomised study medication. Then, 15 minutes (min), 30 min,1 hour (h),2h,3h,4h,6h,8h,12 h and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 - 24h (AUC 0-24) Response</measure>
    <time_frame>Baseline FEV1 taken at visit 2 prior to the first dose of randomised study medication. Then, 15 minutes (min), 30 min,1 hour (h),2h,3h,4h,6h,8h,12 h and 24 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of bronchodilator effect and maximum effect</measure>
    <time_frame>15 minutes (min), 30 min,1 hour (h),2h,3h,4h,6h,8h,12 h and 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>predose and up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Tiotropium 18 mcg dry powder for inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium 18 mcg dry powder for inhalation, one inhalation, once daily with the DISCAIR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPIRIVA 18 mcg HANDIHALER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium 18 mcg dry powder capsul for inhalation one capsule once daily with the HandiHaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 18 mcg</intervention_name>
    <description>tiotropium 18 mcg once a day</description>
    <arm_group_label>Tiotropium 18 mcg dry powder for inhalation</arm_group_label>
    <arm_group_label>SPIRIVA 18 mcg HANDIHALER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 40 years and older with moderate to severe COPD diagnosis

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  Patients with established clinical COPD and severity defined as a post-broncodilator
             FEV1/FVC ratio of ≤0.70 and FEV1 ≤80 % of predicted normal at screening

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Have no excacerbation within last 4 weeks

          -  Hava capability of communicate with investigator

          -  Accept to adapt the procedures of study protocol

          -  Signed and dated informed consent

        Exclusion Criteria:

          -  History of hypersensitivity to anticholinergics

          -  Diagnosis of asthma

          -  History of alergic rinit and athopy

          -  Current or history of lung cancer

          -  Known symptomatic prostatic hypertrophy requiring drug therapy

          -  Known narrow-angle glaucoma requiring drug therapy

          -  Have experienced exacerbation of COPD or lower respiratory inflammatory disease
             requiring use of antibiotics, oral or parenteral corticosteroids (CS) within 4 weeks
             prior to screening visit and/or during run-in period

          -  Patients vaccinated with poored virüs vaccinate within 2 weeks prior to screening
             visit and/or during run-in period

          -  Patients with a recent history of myocardial infarction, acute ischemic cardiac
             disease or severe cardiac arrhythmia requiring drug therapy

          -  Women who are pregnant or lactating or are planning on becoming pregnant during the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neutec Ar-Ge San ve Tic A.S</last_name>
    <role>Study Director</role>
    <affiliation>Neutec Ar-Ge San ve Tic A.S Clinical Trial</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FEV1</keyword>
  <keyword>FVC</keyword>
  <keyword>AUC 0-24</keyword>
  <keyword>bronchodilator efficacy</keyword>
  <keyword>tiotropium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

